Advertisement

Disorders of Phosphate: Hypophosphatemia

  • Alluru S. ReddiEmail author
Chapter

Abstract

Hypophosphatemia is defined as serum [Pi] < 2.5 mg/dL. Patients receiving mannitol develop pseudohypophosphatemia, which is caused by the binding of mannitol to the molybdate used to determine the serum [Pi]. Hypophosphatemia can be severe (serum [Pi] < 1.0 mg/dL), moderate (serum [Pi] 1.0–1.9 mg/dL), or mild (serum [Pi] 2.0–2.5 mg/dL). Severe hypophosphatemia can occur in patients with prolonged use of antacids, such as aluminum hydroxide, magnesium hydroxide, or calcium carbonate or acetate. Moderate hypophosphatemia may be symptomatic or asymptomatic. Hypophosphatemia is rather uncommon in the general population. However, the incidence of hypophosphatemia in hospitalized patients with sepsis, chronic alcoholism, and chronic obstructive pulmonary disease (COPD) is high. Patients with trauma also have high incidence of hypophosphatemia. The causes are varied, but can be conveniently grouped under four categories.

Keywords

Hypophosphatemia Pseudohypophosphatemia Mannitol Fanconi syndrome X-linked hypophosphatemia Autosomal dominant hypophosphatemic rickets (ADHR) Autosomal recessive hypophosphatemic rickets (ARHR) 

Study Questions

  1. 1.
    Taylor BE, Huey WY, Buchman TG, et al. Treatment of hypophosphatemia using a protocol based on patient weight and serum phosphorus level in a surgical intensive care unit (see comment). J Am Coll Surg. 2004;198:198–204.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. 9.
    Amanjadeh J, Reilly RF Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nature Clin Pract Nephrol. 2006;2:136–48.CrossRefGoogle Scholar
  2. 2.
    Bacchetta I, Salusky I. Evaluation of hypophosphatemia: lesions from patients with genetic disorders. Am J Kidney Dis. 2012;59:152–9.PubMedCrossRefGoogle Scholar
  3. 8.
    Brunelli SM, Goldfarb S. Hypophosphatemia: clinical consequences and management. J Am Soc Nephrol. 2007;18:1999–2003.PubMedCrossRefGoogle Scholar
  4. 3.
    Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. Am J Kidney Dis. 2012;60:655–61.PubMedCrossRefGoogle Scholar
  5. 6.
    Geerse DA, Bindels AJ, Kuiper MA, et al. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care. 2010;14:R147.PubMedCrossRefGoogle Scholar
  6. 1.
    Hruska KA, Levi M, Slatopolsky E. Disorders of phosphorus, calcium, and magnesium metabolism. In: Coffman TM, Falk RJ, Molitoris BA, et al, editors. Schrier’s diseases of the kidney. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. pp. 2116–81.Google Scholar
  7. 4.
    Imel EA, Econs MJ. Approach to the hypophosphatemic patient. J Clin Endocrinol Metab. 2012;97:696–706.PubMedCrossRefGoogle Scholar
  8. 7.
    Liams G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia: a review. Q J Med. 2010;103:449–59.CrossRefGoogle Scholar
  9. 5.
    Smogorzewski MJ, Rude RK, Yu ASL. Disorders of calcium, magnesium, and phosphate balance. In: Taal MW, Chertow GM, Marsden PA, et al, editors. Brenner & Rector’s the kidney. 9th ed. Philadelphia: Saunders; 2012. pp. 689–725.CrossRefGoogle Scholar
  10. 10.
    Tennenhouse HS, Murer H. Disorders of renal tubular phosphate transport. J Am Soc Nephrol. 2003;14:240–7.CrossRefGoogle Scholar
  11. 11.
    Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine. 2000;79:1–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Medicine Division of Nephrology and HypertensionRutgers New Jersey Medical SchoolNewarkUSA

Personalised recommendations